Novartis has significantly expanded its global research and development footprint by making India its largest R&D and corporate hub outside Switzerland. The company’s Hyderabad Corporate Center now stands as one of Novartis’s most important global centers for biomedical research, drug development, and digital innovation.
Hyderabad Corporate Center: A Global GCC
Located in Hyderabad, the Novartis Corporate Center employs over 9,000 professionals, accounting for nearly 11% of Novartis’s global workforce. The center integrates biomedical research with advanced drug development and digital technologies, positioning it as a high-impact Global Capability Centre (GCC).
Role in Global Innovation
The Hyderabad hub plays a critical role in the development of new medicines across Novartis’s global pipeline. Indian teams contribute to almost every late-stage drug project and leverage advanced technologies such as artificial intelligence and gene therapy to accelerate innovation.
Two Decades of Growth
The Novartis presence in India has been steadily growing for over 20 years, evolving from a support center into a strategic innovation engine. This long-term expansion reflects India’s increasing importance in Novartis’s global R&D and enterprise strategy.
Why It Matters
Novartis’s decision reinforces India’s position as a global hub for high-value R&D and GCC-led innovation. It also highlights the country’s growing role in shaping the future of biomedical research, drug discovery, and global healthcare solutions.
Key Takeaway
With its Hyderabad Corporate Center now the largest outside Switzerland, Novartis underscores India’s emergence as a strategic center for global R&D, innovation, and enterprise transformation.
Visit Our News section and follow us on LinkedIn and Twitter
Read more full news: Here
